Related coverage linked through entity extraction aliases.
Aug 23, 2026
Alumis reported that 54% of psoriasis patients achieved complete skin clearance (PASI 100) at 48 weeks in the ONWARD3 study, with 75% achieving PASI 90. The company plans to submit an NDA for envudeucitinib in Q4 2026.
Aug 17, 2026
Alpha-synuclein biomarkers in saliva, skin, and CSF show diagnostic promise for Parkinson's disease, with seed amplification assays demonstrating high sensitivity and specificity. Salivary gland biopsies and oral brushings are being studied as less invasive detection methods, though clinical implementation still faces challenges.
Aug 13, 2026
FDA cleared Quantum Biopharma's IND for a Phase 2 trial of Lucid-MS in MS. Biogen's BIIB091 Phase 2 trial reached completion, and Bial concluded its ACTIVATE Phase IIb treatment period for GBA-PD.
Jul 28, 2026
BIIB122 failed to slow Parkinson's progression in the Phase 2b LUMA study, missing primary and secondary endpoints. Biogen and Denali will discontinue the drug in idiopathic Parkinson's disease; Denali continues the BEACON study in LRRK2 carriers.
Jul 31, 2026
Prothena Corporation plc will report its second quarter and first six months of 2026 financial results on August 6, 2026, after U.S. market close. No conference call will be held, consistent with past practice. The company focuses on neurodegenerative and rare amyloid diseases.
Aug 04, 2026
AbbVie's Q2 2026 revenue hit $16.99 billion, beating estimates, but full-year EPS guidance was cut to $13.97. Growth in immunology and neuroscience continued, and the FAST study on ubrogepant wrapped up.
May 16, 2026
CU Anschutz's online Community Hospice and Palliative Medicine Fellowship helps mid-career physicians become board certified in palliative care while working. The program aims to address a national clinician shortage through a flexible, part-time model and interdisciplinary care training.
Jun 23, 2026
Cerebral organoids are revealing how Ebola virus persists, aiding treatment research for rare Parkinson's disease, modeling Alzheimer's, and gaining whole-network recording capabilities.
Aug 05, 2026
Oncotelic granted Lunai Bioworks worldwide rights to its nose-to-brain delivery system for biodefense and Alzheimer's. Nearly 98% of small-molecule drugs fail to cross the blood-brain barrier.
Jun 11, 2026
A review of ClinicalTrials.gov registrations found few late-stage trials with robust sleep outcome measures in elderly Parkinson's disease patients. The analysis in BMC Geriatrics highlights outcome measure heterogeneity, underrepresentation of older adults, and short study durations as key gaps.
Jun 16, 2026
Recent studies associate blood biomarkers with brain atrophy and cognitive decline in Alzheimer's disease, while new DNA aptamers, retinal imaging, and speech analysis advance neurodegeneration detection and monitoring.
May 13, 2026
Aprea, Gain, and Grace Therapeutics posted quarterly updates featuring APR-1051 partial responses, an 81% average CSF GluSph reduction for GT-02287, and an April 23, 2026 PDUFA date for GTx-104.
Aug 02, 2026
The global CNS therapeutics market was valued at USD 127.29 billion in 2025 and is projected to reach USD 285.72 billion by 2035, driven by demand for Alzheimer’s and Parkinson’s treatments. North America held 45% of the market; neurodegenerative diseases were the largest segment. Private investment and trends toward biologics and AI are shaping the sector.
Jul 13, 2026
Serina Therapeutics completes sentinel dosing in Cohort 1 of its Phase Ib registrational trial of SER-252 for advanced Parkinson's disease. Safety review recommends continuation; enrollment and dosing ongoing. FDA alignment on 505(b)(2) pathway and registrational status.
Jul 03, 2026
Bayer outlined its 2030 growth strategy at Pharma Media Day 2026, driven by AI partnerships, precision medicine, and a strengthened pipeline. The company aims for mid-single-digit growth from 2027 and 30% margins by 2030.
Jun 27, 2026
ACADIA Pharmaceuticals' stock jumped after the European Medicines Agency recommended approval of its Rett syndrome drug Daybue. The company also reported strong quarterly results and progress on its Alzheimer's disease psychosis treatment.
Jun 25, 2026
MRI-guided brain stimulation achieved 80% response rates for treatment-resistant depression versus 60% with conventional targeting, per a JAMA Psychiatry study. Separately, Barcelona researchers developed an MRI tool to accurately identify rare neurodegenerative tauopathies PSP and CBD, while experts in Paris discussed AI's growing role in predictive psychiatry.
Jun 22, 2026
Research estimates 300 million people worldwide live with rare diseases, yet only 5% of conditions have approved treatments. Patients face diagnostic delays of 4.7 to 8 years, with emerging AI and machine learning tools showing promise in accelerating diagnosis and drug development.
Jun 19, 2026
A $9 million grant from ASAP and The Michael J. Fox Foundation funds an Indiana University-led study on immune cell exhaustion in Parkinson's disease, aiming to develop personalized immunotherapies. The multi-institutional team will map immune system changes to uncover biomarkers and explain disease heterogeneity. Advances in proteomics are also enabling molecular subtyping and precision medicine across neurological disorders.
Jun 11, 2026
Japan's health ministry panel is reviewing two regenerative cell therapies for Parkinson's disease and heart failure, testing the country's push to build a domestic cell-based treatment industry. Japan's cell culture market is projected to reach USD 2.34 billion by 2031, driven by government support and favorable regulatory pathways. Australian firm Cartherics secured a Japanese patent for its iPSC-based immune cell therapies.
